Black Diamond Therapeutics Share Price Today: Live Updates & Key Insights

Black Diamond Therapeutics share price today is $2.18, up -1.86%. The stock opened at $2.15 against the previous close of $2.15, with an intraday high of $2.185 and low of $2.07.

Black Diamond Therapeutics Share Price Chart

Black Diamond Therapeutics

us-stock
To Invest in {{usstockname}}
us-stock

Black Diamond Therapeutics Share Price Performance

$2.18 -0.0186(-1.86%) BDTX at 23 Mar 2026 12:11 PM Biotechnology
Lowest Today 2.07
Highest Today 2.185
Today’s Open 2.15
Prev. Close 2.15
52 Week High 4.94
52 Week Low 1.20
Day’s Range: Low 2.07 High 2.185
52-Week Range: Low 1.20 High 4.94
1 day return -
1 Week return -4.33
1 month return -13.07
3 month return -19.57
6 month return -38.65
1 year return +24.7
3 year return +15.74
5 year return -91.71
10 year return -

Black Diamond Therapeutics Institutional Holdings

T. Rowe Price Investment Management,Inc. 18.86

NEA Management Company, LLC 7.81

T. Rowe Price US Small-Cap Core Equity 4.65

T. Rowe Price Small-Cap Stock 4.64

Vanguard Group Inc 3.84

T. Rowe Price Small-Cap Value 3.74

TANG CAPITAL MANAGEMENT LLC 3.63

T. Rowe Price Instl Small-Cap Stock 2.45

T. Rowe Price U.S. SC Value Eq Tr-D 2.38

Vanguard Total Stock Mkt Idx Inv 2.28

T. Rowe Price U.S. SC Core Eq Tr-D 2.25

Marshall Wace Asset Management Ltd 1.95

Siren, L.L.C. 1.84

Arrowstreet Capital Limited Partnership 1.83

BlackRock Inc 1.80

Jane Street Group LLC 1.69

Renaissance Technologies Corp 1.67

Vestal Point Capital LP 1.53

Dimensional Fund Advisors, Inc. 1.50

D. E. Shaw & Co LP 1.15

Connor Clark & Lunn Inv Mgmt Ltd 1.15

UBS Group AG 1.10

Awm Investment Company Inc 1.10

FMR Inc 0.95

T. Rowe Price US Smlr Coms Eq A 0.93

Geode Capital Management, LLC 0.89

Northern Trust Corp 0.86

Acadian Asset Management LLC 0.84

Vanguard Institutional Extnd Mkt Idx Tr 0.82

Fidelity Enhanced Small Cap ETF 0.79

iShares Biotechnology ETF 0.59

Northern Small Cap Value 0.49

NT Quality Small Cap Value 0.49

Fidelity Extended Market Index 0.42

EA Bridgeway Omni Small-Cap Value ETF 0.39

Northwestern Mutual Ser Small Cap Value 0.35

T. Rowe Price Small-Cap Value Equity 0.35

Dimensional US Small Cap ETF 0.32

Mackenzie GQE US Small Cap F8 0.31

DFA US Small Cap I 0.30

Black Diamond Therapeutics Market Status

Strong Buy: 3

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Black Diamond Therapeutics Fundamentals

Market Cap 120.22 M

PB Ratio 0.971

PE Ratio 5.7027

Enterprise Value 6.66 M

Total Assets 143.01 M

Volume 725839

Black Diamond Therapeutics Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:-437000 -0.4M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-82442000 -82.4M, FY22:-84520000 -84.5M, FY21:-123203000 -123.2M, FY20:-65479000 -65.5M, FY19:-41143000 -41.1M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:70000000 70.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-86000 -0.1M, Q1/2025:70000000 70.0M, Q3/2024:-86000 -0.1M, Q2/2024:-86000 -0.1M

Quarterly Net worth Q3/2025:-8498000 -8.5M, Q2/2025:-10561000 -10.6M, Q1/2025:56542000 56.5M, Q3/2024:-15557000 -15.6M, Q2/2024:-19909000 -19.9M

About Black Diamond Therapeutics & investment objective

Company Information Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 24

Industry Biotechnology

CEO Dr. Mark A. Velleca M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Black Diamond Therapeutics FAQs

What is the share price of Black Diamond Therapeutics today?

The current share price of Black Diamond Therapeutics is $2.18.

Can I buy Black Diamond Therapeutics shares in India?

Yes, Indian investors can buy Black Diamond Therapeutics shares by opening an international trading and demat account with Motilal Oswal.

How to buy Black Diamond Therapeutics shares in India?

You can easily invest in Black Diamond Therapeutics shares from India by:

Can I buy fractional shares of Black Diamond Therapeutics?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Black Diamond Therapeutics?

Black Diamond Therapeutics has a market cap of $120.22 M.

In which sector does Black Diamond Therapeutics belong?

Black Diamond Therapeutics operates in the Biotechnology sector.

What documents are required to invest in Black Diamond Therapeutics stocks?

To invest, you typically need:

What is the PE and PB ratio of Black Diamond Therapeutics?

The PE ratio of Black Diamond Therapeutics is 5.70 and the PB ratio is 0.97.